Skip to main content
Clinical Trials/NCT05401500
NCT05401500
Unknown
Not Applicable

ACTA2 and Familial Aortopathies: Creation and Validation of an Exploratory Cellular Model

Assistance Publique Hopitaux De Marseille1 site in 1 country3 target enrollmentJune 1, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Familial Aortopathies
Sponsor
Assistance Publique Hopitaux De Marseille
Enrollment
3
Locations
1
Primary Endpoint
analysis of the impact of ACTA2 mutations on the morphology of the actin cytoskeleton
Last Updated
3 years ago

Overview

Brief Summary

The prevalence of hereditary aortic disease (HTAD), responsible for aneurysm or dissection, is estimated at 25%. Mutations in the ACTA2 gene represent the main cause of non-syndromic forms (10-21%). ACTA2 is expressed in vascular wall smooth muscle cells (VSMC) and encodes alpha actin (α-SMA). This actin isoform is in the majority in VSMCs and plays a key role in their contractile properties. The mutations are dominant-negative and lead, in a fibroblast model, to defects in the organisation of the actin cytoskeleton and to an increase in the migratory and proliferative potential of the cells. In vivo, VSCMs exist in a phenotypic continuum ranging from a quiescent differentiated contractile state to a so-called synthetic state in which cells are proliferative, synthesise extracellular matrix elements and exhibit enhanced migratory capabilities. To understand how ACTA2 mutations deregulate VSMC functions and steer them towards a synthetic phenotype, it is necessary to have a cellular model as close as possible to the affected tissue..

Registry
clinicaltrials.gov
Start Date
June 1, 2022
End Date
June 1, 2023
Last Updated
3 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • patient with a mutation in the ACTA2 gene

Exclusion Criteria

  • patient under 18 years of age at the time of inclusion

Outcomes

Primary Outcomes

analysis of the impact of ACTA2 mutations on the morphology of the actin cytoskeleton

Time Frame: baseline

use of a model of IPS cells reprogrammed into VSMCs from patients with ACTA2 mutations, compared to a healthy control

Study Sites (1)

Loading locations...

Similar Trials